Please select the arm or intervention descriptions that belong to the clinical trial below.
Title: Effect of Liraglutide on Body Weight in Non-diabetic Obese Subjects or Overweight Subjects With Co-morbidities: A Randomised, Double-blind, Placebo Controlled, Parallel Group, Multi-centre, Multinational Trial With Stratification of Subject to Either 56 or 160 Weeks of Treatment Based on Pre-diabetes Status at Randomisation
Brief Summary: This trial is conducted in Africa, Asia, Europe, Oceania, North America and South America.

The aim of this clinical trial is to evaluate the potential of liraglutide to induce and maintain weight loss over 56 weeks in obese subjects or overweight subjects with co-morbidities. Furthermore, the aim is to investigate the long term potential of liraglutide to delay the onset of type 2 diabetes in subjects diagnosed with pre-diabetes at baseline.

Based on body mass index (BMI) and pre-diabetes status, subjects will be randomised to either 68 weeks (56 weeks of randomised treatment followed by a 12 week re-randomised treatment period) or 160 weeks of treatment (160 week treatment will only be applicable to subjects with pre-diabetes status at baseline).


Options:
A: Arm Label: intermittent energy restriction; Type: EXPERIMENTAL; Interventions: Other: dietary intervention intermittent energy restriction | Arm Label: continuous energy restriction; Type: ACTIVE_COMPARATOR; Interventions: Other: continuous energy restriction | Intervention Type: OTHER; Name: dietary intervention intermittent energy restriction; Assigned to Arm(s): intermittent energy restriction | Intervention Type: OTHER; Name: continuous energy restriction; Assigned to Arm(s): continuous energy restriction
B: Arm Label: Intermittent Energy Restriction; Type: EXPERIMENTAL; Interventions: Behavioral: Intermittent Energy Restriction | Arm Label: Continuous Energy Restriction; Type: ACTIVE_COMPARATOR; Interventions: Behavioral: Continuous Energy Restriction | Intervention Type: BEHAVIORAL; Name: Intermittent Energy Restriction; Assigned to Arm(s): Intermittent Energy Restriction | Intervention Type: BEHAVIORAL; Name: Continuous Energy Restriction; Assigned to Arm(s): Continuous Energy Restriction
C: Arm Label: Alternate day fasting; Type: ACTIVE_COMPARATOR; Interventions: Behavioral: Alternate day fasting | Arm Label: control group; Type: NO_INTERVENTION; Interventions: N/A | Intervention Type: BEHAVIORAL; Name: Alternate day fasting; Assigned to Arm(s): Alternate day fasting
D: Arm Label: Liraglutide 3.0mg (week0-56)/Liraglutide 3.0mg (week56-68); Type: EXPERIMENTAL; Interventions: Drug: liraglutide | Arm Label: Liraglutide 3.0mg (week0-56)/Liraglutide Placebo (week56-68); Type: EXPERIMENTAL; Interventions: Drug: placebo | Arm Label: Liraglutide Placebo, no Pre-diabetes; Type: PLACEBO_COMPARATOR; Interventions: Drug: placebo | Arm Label: Liraglutide 3.0mg, Pre-diabetes; Type: EXPERIMENTAL; Interventions: Drug: liraglutide | Arm Label: Liraglutide Placebo, Pre-diabetes; Type: PLACEBO_COMPARATOR; Interventions: Drug: placebo | Intervention Type: DRUG; Name: liraglutide; Assigned to Arm(s): Liraglutide 3.0mg (week0-56)/Liraglutide 3.0mg (week56-68) | Intervention Type: DRUG; Name: placebo; Assigned to Arm(s): Liraglutide 3.0mg (week0-56)/Liraglutide Placebo (week56-68), Liraglutide Placebo, no Pre-diabetes | Intervention Type: DRUG; Name: liraglutide; Assigned to Arm(s): Liraglutide 3.0mg, Pre-diabetes | Intervention Type: DRUG; Name: placebo; Assigned to Arm(s): Liraglutide Placebo, Pre-diabetes

Answer: D